|
C14ORF109 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
1.218550E-03 |
| Normal-vs-Stage3 |
1.62814206561279E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
4.295400E-03 |
| Stage1-vs-Stage3 |
4.163000E-01 |
| Stage1-vs-Stage4 |
3.240500E-04 |
| Stage2-vs-Stage3 |
1.378050E-03 |
| Stage2-vs-Stage4 |
1.26170000003256E-06 |
| Stage3-vs-Stage4 |
1.495550E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.88119999577907E-08 |
| Normal-vs-Asian |
7.09620140426637E-11 |
| Caucasian-vs-AfricanAmerican |
9.743200E-01 |
| Caucasian-vs-Asian |
5.682600E-01 |
| AfricanAmerican-vs-Asian |
7.340400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
6.66133814775094E-16 |
| Male-vs-Female |
1.215980E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62547753035369E-12 |
| Normal-vs-Age(61-80Yrs) |
2.40709674415029E-11 |
| Normal-vs-Age(81-100Yrs) |
3.82389999999955E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.855400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.378400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.852200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.809400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.321800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.784000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.595680E-03 |
| Classical-VS-Follicular |
1.604000E-04 |
| Classical-VS-Other |
7.632200E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.06540000044397E-07 |
| Tall-VS-Other |
4.692600E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
1.668150E-01 |
| Follicular-VS-Normal |
3.75950000000014E-05 |
| Other-VS-Normal |
4.43749999999854E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.01909591876392E-11 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.64469999952566E-07 |
|
|
